<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281124</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02570</org_study_id>
    <secondary_id>NCI-2011-02570</secondary_id>
    <secondary_id>CDR0000692184</secondary_id>
    <secondary_id>OSU-10100</secondary_id>
    <secondary_id>OSU 10100</secondary_id>
    <secondary_id>8617</secondary_id>
    <secondary_id>N01CM00070</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <nct_id>NCT01281124</nct_id>
  </id_info>
  <brief_title>Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Pilot Phase II Study of 5-Azacytidine in Previously Treated Patients With Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II clinical trial is studying how well azacitidine works in treating patients with&#xD;
      previously treated advanced non-small cell lung cancer. Drugs used in chemotherapy, such as&#xD;
      azacitidine, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the ability of 5-azacytidine to cause DNA hypomethylation and re-expression&#xD;
      of silenced tumor suppressor genes when stratified for high or low expression of mir29a, b,&#xD;
      and c.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To compare the molecular studies (mir29 expression and tumor suppressor gene methylation)&#xD;
      between archival tissue, fresh biopsy pre-treatment samples, and post-treatment fresh&#xD;
      samples.&#xD;
&#xD;
      II. To determine the overall response rate by CT (RECIST 1.1 criteria) and PET (EORTC PET&#xD;
      response criteria), PFS, and OS of patients treated with azacytidine in the second- or&#xD;
      third-line setting.&#xD;
&#xD;
      III. To correlate the blood microRNA profiles (and changes in microRNA profiles) with&#xD;
      response to azacytidine.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo tissue and blood sample collection at baseline and periodically during study&#xD;
      treatment for correlative studies. After completion of study treatment, patients are followed&#xD;
      up for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2011</start_date>
  <completion_date type="Actual">September 12, 2012</completion_date>
  <primary_completion_date type="Actual">April 15, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes When Stratified for Low or High Expression of mir29</measure>
    <time_frame>Up to 12 weeks after completion of study treatment</time_frame>
    <description>The change in mean methylation of the genes between the patients with a low mir29 and a high mir29 expression will be evaluated by a two-sample t-test. Secondary analyses include a multivariate regression where all 5 changes in methylation will be regressed on mir29 expression (low vs. high) and adjusted for patient demographic and clinical attributes at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the day of initial treatment until death (from any cause), assessed up to 12 weeks after completion of study treatment</time_frame>
    <description>Analyzed using a Kaplan-Meier methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From the day of initial treatment until documented disease progression (per PET) or death, assessed up to 12 weeks after completion of study treatment</time_frame>
    <description>Analyzed using a Kaplan-Meier methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Recurrent Lung Non-Small Cell Carcinoma</condition>
  <condition>Stage IV Lung Non-Small Cell Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Treatment (azacitidine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Treatment (azacitidine)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced (stage 4 or recurrent) NSCLC, not eligible for any curative intent treatment&#xD;
&#xD;
               -  Tumor must be histologically or cytologically confirmed&#xD;
&#xD;
          -  Measurable disease (as defined by RECIST criteria)&#xD;
&#xD;
          -  Patients may have up to two (and at least one) prior cytotoxic regimens in the&#xD;
             metastatic setting&#xD;
&#xD;
               -  Prior adjuvant chemotherapy following resection or definitive chemo-radiation for&#xD;
                  patients with locally advanced disease is not included in this&#xD;
&#xD;
               -  Allowable systemic therapy in the metastatic setting includes 2 cytotoxic&#xD;
                  regimens and erlotinib and/or other non-cytotoxic drugs (i.e., erlotinib,&#xD;
                  sorafenib, and other tyrosine kinase inhibitors do not count as a &quot;cytotoxic&#xD;
                  regimen&quot;)&#xD;
&#xD;
               -  Prior adjuvant therapy or definitive chemo-radiation is allowed if completed &gt;&#xD;
                  six months before the onset of &quot;first-line&quot; therapy in the metastatic setting -&#xD;
                  in this setting, adjuvant or definitive chemo-radiation will not &quot;count&quot; as one&#xD;
                  of the two cytotoxic regimens; if however, the patient relapses within six months&#xD;
                  from completion of adjuvant or definitive chemoradiation, then this therapy will&#xD;
                  be considered the first-line cytotoxic therapy&#xD;
&#xD;
               -  In the unusual circumstance where patients receive &quot;adjuvant&quot; therapy following&#xD;
                  resection of oligo-metastatic disease (for example brain metastasis and lung&#xD;
                  primary resections) and the treating physician decides to administer chemotherapy&#xD;
                  following all surgery, this will be considered &quot;adjuvant&quot; therapy and the same&#xD;
                  rules as noted above will apply for initiation of first-line systemic therapy&#xD;
&#xD;
          -  No patients with uncontrolled brain metastases or leptomeningeal disease&#xD;
&#xD;
               -  Patients with controlled brain metastases are allowed&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets ≥ 100,000 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 gm/100 mL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  No patients who are pregnant&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test&#xD;
&#xD;
          -  The patient must be willing to use adequate contraception for the duration of study&#xD;
             treatment and up to four weeks following the last dose of drug&#xD;
&#xD;
          -  Archival diagnostic material sufficient for microRNA evaluation/assessment is&#xD;
             preferred, though optional&#xD;
&#xD;
               -  The presence of archival material will not preclude the need for pre and post&#xD;
                  treatment biopsies&#xD;
&#xD;
          -  Willing to undergo biopsy pre-treatment and following first cycle&#xD;
&#xD;
               -  Biopsy may be from any accessible site (primary or metastatic)&#xD;
&#xD;
          -  No known HIV or hepatitis B or C (though testing for this is not required)&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               -  Symptomatic CHF&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Serious cardiac arrhythmia&#xD;
&#xD;
               -  Serious infection&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No patients who have significant psychiatric illness that, in the opinion of the&#xD;
             principal investigator, would prevent adequate informed consent or render therapy&#xD;
             unsafe&#xD;
&#xD;
          -  Patients may not have had a prior invasive malignancy except for adequately treated&#xD;
             non-melanoma cell skin cancer, in situ cervical cancer, or other cancer for which the&#xD;
             patient has been disease-free for 2 years&#xD;
&#xD;
               -  For example, a stage 1 (T1c) prostate cancer 2 years prior to a diagnosis of&#xD;
                  NSCLC would not be exclusionary, however, a metastatic prostate cancer currently&#xD;
                  receiving hormonal or chemotherapy would be excluded&#xD;
&#xD;
          -  No other concurrent palliative radiotherapy&#xD;
&#xD;
          -  Recovered from prior surgery, radiation, or chemotherapy to ≤ grade 2 toxicity&#xD;
&#xD;
          -  Palliative radiation or surgical procedures (for example, endobronchial therapy) is&#xD;
             allowed, but must have been completed &gt; 2 weeks prior to starting treatment&#xD;
&#xD;
          -  No other investigational or commercial agents or therapies may be administered with&#xD;
             the intent to treat the patient's malignancy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A Otterson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <results_first_submitted>May 15, 2013</results_first_submitted>
  <results_first_submitted_qc>September 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 13, 2013</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (5-Azacytidine)</title>
          <description>Patients receive 5-azacitidine subcutaneously at the starting dose level of 75 mg/m2 on an outpatient basis daily for 7 days on a 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Azacitidine)</title>
          <description>Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes When Stratified for Low or High Expression of mir29</title>
        <description>The change in mean methylation of the genes between the patients with a low mir29 and a high mir29 expression will be evaluated by a two-sample t-test. Secondary analyses include a multivariate regression where all 5 changes in methylation will be regressed on mir29 expression (low vs. high) and adjusted for patient demographic and clinical attributes at baseline.</description>
        <time_frame>Up to 12 weeks after completion of study treatment</time_frame>
        <population>Data analysis was not done due to low accrual for this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (5-Azacyitidine)</title>
            <description>Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>DNA Hypomethylation and Re-expression of Silenced Tumor Suppressor Genes When Stratified for Low or High Expression of mir29</title>
          <description>The change in mean methylation of the genes between the patients with a low mir29 and a high mir29 expression will be evaluated by a two-sample t-test. Secondary analyses include a multivariate regression where all 5 changes in methylation will be regressed on mir29 expression (low vs. high) and adjusted for patient demographic and clinical attributes at baseline.</description>
          <population>Data analysis was not done due to low accrual for this trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Analyzed using a Kaplan-Meier methods.</description>
        <time_frame>From the day of initial treatment until death (from any cause), assessed up to 12 weeks after completion of study treatment</time_frame>
        <population>Data analysis was not done due to low accrual for this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (5-Azacytidine)</title>
            <description>Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Analyzed using a Kaplan-Meier methods.</description>
          <population>Data analysis was not done due to low accrual for this trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>Analyzed using a Kaplan-Meier methods.</description>
        <time_frame>From the day of initial treatment until documented disease progression (per PET) or death, assessed up to 12 weeks after completion of study treatment</time_frame>
        <population>Data analysis was not done due to low accrual for this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Azacitidine)</title>
            <description>Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>Analyzed using a Kaplan-Meier methods.</description>
          <population>Data analysis was not done due to low accrual for this trial.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through end of follow up period (12 weeks after removal from study or until death, whichever occurs first).</time_frame>
      <desc>Patients removed from study for unacceptable adverse events will be followed until resolution or stabilization of the adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Azacitidine)</title>
          <description>Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <description>event occurred after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pericardial tamponade</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>event occured after removal from study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia-Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria (Welts)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to low enrollment of this trial all outcomes were not assessed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Greg Otterson</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-2887</phone>
      <email>Greg.Otterson@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

